Jennifer A. Pruskowski, PharmD, BCPS, BCGP, CPE led by Dr. Yael Schenker, MD, MAS, received a grant from the Palliative Care Research Cooperative Group. The study will complete a secondary analysis of the landmark de-prescribing trial, “Safety and Benefit of Discontinuing Statin Therapy in the Setting of Advanced, Life-Limiting Illness”. Research is aimed to explore associations between polypharmacy, symptom burden, and quality of life in patients with advanced, life-limiting illness. This work will further describe the role of de-prescribing and its impact on patient-oriented outcomes.
Pruskowski is an assistant professor in the pharmacy and therapeutics department at PittPharmacy.
Jennifer A. Pruskowski, PharmD, BCPS, BCGP, CPE led by Dr. Yael Schenker, MD, MAS, received a grant from the Palliative Care Research Cooperative Group. The study will complete a secondary analysis of the landmark de-prescribing trial, “Safety and Benefit of Discontinuing Statin Therapy in the Setting of Advanced, Life-Limiting Illness”. Research is aimed to explore associations between polypharmacy, symptom burden, and quality of life in patients with advanced, life-limiting illness. This work will further describe the role of de-prescribing and its impact on patient-oriented outcomes.
Pruskowski is an assistant professor in the pharmacy and therapeutics department at PittPharmacy.
